Ocular's sustained-release insert misses bull's-eye in phase 3 glaucoma trial

Ocular Therapeutix’s drug-eluting insert to treat glaucoma—a small, resorbable hydrogel plug that sits within the tear duct designed to replace 90 days’ worth of daily eye drops—fell just short of meeting the primary endpoint of its first pivotal phase 3 trial.